A young infant from Dubai, Adnan, has made a remarkable recovery after being treated with an experimental medication for his rare form of genetic epilepsy. Born with a condition that caused him to have a seizure every 13 minutes, Adnan's life was turned around when he received the still-experimental drug ABS-1230. The treatment, which targets abnormal activity in an ion channel associated with Adnan's condition, was administered by a team led by Professor Ubaid Shah at King's College Hospital London in Dubai. Following the treatment, Adnan was discharged from the hospital just a week later, with no seizures recorded during that time. As of November 2nd, the infant remains seizure-free, and is even beginning to pass early development milestones. While the treatment is still experimental and requires further research, Adnan's response has been incredibly positive, giving hope to families affected by similar conditions. The Dubai Health Authority granted the application for the treatment through a compassionate use pathway, allowing Adnan to receive the medication outside of clinical trials. This breakthrough highlights the potential of precision medicine in treating genetic diseases, and the importance of continued research in this area.
Infant Goes from 110 Seizures a Day to Seizure-Free with Experimental Treatment
Prepared with AI assistance; not independently fact-checked. Original source: Good News Network